Zonghai Li M.D., Ph.D., is dedicated himself to develop innovative treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become the most widely used unnatural peptide in antitumor study now. He is the inventor of many new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; Run-CAR technology to increase the antitumor activities of chimeric antigen receptor (CAR) T cells. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide.